Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06520345 · ClinicalTrials.gov registry record · Phase 3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 430
- Enrollment target
- 15
- Study locations
NCT06520345: Recruiting Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
NCT06520345 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Telix Pharmaceuticals (Innovations) Pty Limited. The registered enrollment target is 430 participants, above the 192-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (124% higher). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06520345, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 430 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Primary Outcome
time from randomization to disease progression confirmed by central independent radiology review according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria (which incorporates Response Evaluation Criteria in Solid Tumors, RECIST 1.1, for soft tissue lesions), or death (whichever occurs first)
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG 177Lu-TLX591
Study Locations (15)
New South Wales
- Westmead Hospital - Sydney
- Nepean Hospital - Sydney
- Wollongong Hospital - Wollongong
Utah
- Intermountain Health - Murray
- Intermountain Health - Salt Lake City
California
- Chao Family Comprehensive Cancer Centre - Orange
Florida
- Biogenix Molecular LLC - Miami
Maryland
- United Theranostics - Glen Burnie
Nebraska
- XCancer Omaha - Omaha
New York
- Columbia University Herbert Irving Comphrensive Cancer Center - New York
Ohio
- University Hospital - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2024-07-26 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
What NCT06520345 shows while recruiting
NCT06520345 is an interventional study that assigns participants to a tested intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (124% higher).
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT06520345 lists 15 locations in 12 states (New South Wales, Utah, California).
Frequently Asked Questions
What is clinical trial NCT06520345 about?
NCT06520345 is a clinical study titled "The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)". The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
What is the current status of trial NCT06520345?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 2024-07-26. Estimated completion is 2030-12.
What conditions does trial NCT06520345 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT06520345?
The interventions under investigation include: Docetaxel (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), 177Lu-TLX591 (DRUG).
Who is sponsoring clinical trial NCT06520345?
This trial is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06520345 being conducted?
This trial has 15 study locations across California, Florida, Maryland, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06520345's enrollment target sits among peer trials
430 10th of 69 higher than 60 of 69 other Metastatic Castration-Resistant Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
RECRUITING · Phase 3
-
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
ACTIVE NOT RECRUITING · Phase 3
-
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI